MRC Laboratory of Molecular Biology, Hills Road, Cambridge CB2 0QH, UK.
Nature. 2011 Jan 13;469(7329):241-4. doi: 10.1038/nature09746.
β-adrenergic receptors (βARs) are G-protein-coupled receptors (GPCRs) that activate intracellular G proteins upon binding catecholamine agonist ligands such as adrenaline and noradrenaline. Synthetic ligands have been developed that either activate or inhibit βARs for the treatment of asthma, hypertension or cardiac dysfunction. These ligands are classified as either full agonists, partial agonists or antagonists, depending on whether the cellular response is similar to that of the native ligand, reduced or inhibited, respectively. However, the structural basis for these different ligand efficacies is unknown. Here we present four crystal structures of the thermostabilized turkey (Meleagris gallopavo) β(1)-adrenergic receptor (β(1)AR-m23) bound to the full agonists carmoterol and isoprenaline and the partial agonists salbutamol and dobutamine. In each case, agonist binding induces a 1 Å contraction of the catecholamine-binding pocket relative to the antagonist bound receptor. Full agonists can form hydrogen bonds with two conserved serine residues in transmembrane helix 5 (Ser(5.42) and Ser(5.46)), but partial agonists only interact with Ser(5.42) (superscripts refer to Ballesteros-Weinstein numbering). The structures provide an understanding of the pharmacological differences between different ligand classes, illuminating how GPCRs function and providing a solid foundation for the structure-based design of novel ligands with predictable efficacies.
β-肾上腺素能受体(βAR)是 G 蛋白偶联受体(GPCR),在与儿茶酚胺激动剂配体(如肾上腺素和去甲肾上腺素)结合后,会激活细胞内 G 蛋白。已经开发出了一些合成配体,可以激活或抑制βAR,用于治疗哮喘、高血压或心功能障碍。这些配体根据其细胞反应与天然配体相似、减弱或抑制的程度,分别被归类为完全激动剂、部分激动剂或拮抗剂。然而,这些不同配体效力的结构基础尚不清楚。在这里,我们展示了四个热稳定的火鸡(Meleagris gallopavo)β(1)-肾上腺素能受体(β(1)AR-m23)的晶体结构,分别与完全激动剂卡莫特罗和异丙肾上腺素以及部分激动剂沙丁胺醇和多巴酚丁胺结合。在每种情况下,激动剂结合都会使儿茶酚胺结合口袋相对于结合的拮抗剂受体收缩 1Å。完全激动剂可以与跨膜螺旋 5 中的两个保守丝氨酸残基(Ser(5.42)和 Ser(5.46))形成氢键,但部分激动剂仅与 Ser(5.42)相互作用(上标指的是 Ballesteros-Weinstein 编号)。这些结构提供了对不同配体类别之间药理学差异的理解,阐明了 GPCR 的功能,并为具有可预测效力的新型配体的基于结构的设计提供了坚实的基础。